Clinical Trials: Country-Specific Clinical Trials

Global Sponsors’ Strategy for China-Inclusive Trials

Posted on digi By digi

Sponsors should plan China-inclusive trials early in global development. Best practices include:
✔️ Aligning protocols with ICH E17 and NMPA requirements
✔️ Engaging CROs with strong China operations
✔️ Expanding site networks beyond Tier-1 hospitals
✔️ Addressing data localization through local IT infrastructure
✔️ Training investigators in global GCP standards
✔️ Proactive regulatory engagement with the NMPA and ethics committees
These practices mitigate risks and ensure smooth integration of China into global programs.

Click to read the full article.

Clinical Trials in China, Country-Specific Clinical Trials

Clinical Trial Insurance Requirements in China

Posted on digi By digi

Sponsors should:
✔️ Secure trial-specific liability insurance early in planning
✔️ Ensure coverage includes medical costs, disability, and death compensation
✔️ Provide transparent insurance documentation to ethics committees
✔️ Negotiate clear indemnification clauses with sites
✔️ Engage CROs to manage local insurance procurement and compliance
These measures reduce approval delays and protect participant rights.

Click to read the full article.

Clinical Trials in China, Country-Specific Clinical Trials

How China’s National Reimbursement Decisions Affect Clinical Development

Posted on digi By digi

Sponsors should:
✔️ Incorporate pharmacoeconomic endpoints early in trial design
✔️ Engage with the NHSA to understand NRDL priorities
✔️ Use RWE to complement clinical data
✔️ Align trial sites with regions prioritized for reimbursement access
✔️ Partner with CROs experienced in pharmacoeconomic data collection
These best practices increase the chances of NRDL inclusion and accelerate patient access.

Click to read the full article.

Clinical Trials in China, Country-Specific Clinical Trials

Role of Big Data and AI in Chinese Clinical Trials

Posted on digi By digi

Sponsors should:
✔️ Validate AI tools through pilot studies before large-scale use
✔️ Ensure compliance with NMPA and PIPL requirements
✔️ Partner with local hospitals and CROs with digital expertise
✔️ Invest in interoperable data platforms for multi-site trials
✔️ Maintain human oversight in AI-driven processes
These practices help sponsors maximize benefits while ensuring compliance and ethics.

Click to read the full article.

Clinical Trials in China, Country-Specific Clinical Trials

Fast-Track Review Channels in China: Breakthrough vs Conditional

Posted on digi By digi

Sponsors should:
✔️ Identify candidates early for fast-track pathways
✔️ Engage the NMPA proactively through consultations
✔️ Design trials incorporating surrogate endpoints where relevant
✔️ Plan robust post-market studies for Conditional Approval
✔️ Coordinate with CROs to manage expedited timelines and inspections
Strategic use of these pathways accelerates approvals while ensuring compliance.

Click to read the full article.

Clinical Trials in China, Country-Specific Clinical Trials

Clinical Research Professional Training Standards in China

Posted on digi By digi

Sponsors and CROs should:
✔️ Require documented GCP training for all trial staff
✔️ Provide refresher courses every three years or with major protocol changes
✔️ Partner with accredited providers for standardized training
✔️ Audit site training records during feasibility and initiation
✔️ Invest in role-specific training (investigator vs CRA vs CRC)
These measures ensure compliance and reduce inspection risks.

Click to read the full article.

Clinical Trials in China, Country-Specific Clinical Trials

Real-World Evidence Studies in Chinese Regulatory Submissions

Posted on digi By digi

Sponsors should:
✔️ Define regulatory objectives for RWE early in development
✔️ Partner with hospitals and registries to ensure data quality
✔️ Implement standardized data cleaning and validation procedures
✔️ Use advanced analytics, including AI, to reduce bias
✔️ Engage regulators early to align expectations on RWE use
✔️ Leverage CROs with expertise in RWE operations in China
These practices enhance the credibility and acceptance of RWE in submissions.

Click to read the full article.

Clinical Trials in China, Country-Specific Clinical Trials

GCP Inspection Trends in China (Recent Findings)

Posted on digi By digi

Sponsors should:
✔️ Conduct mock inspections and internal audits
✔️ Ensure complete and accurate TMF documentation
✔️ Maintain validated electronic systems with audit trails
✔️ Provide regular GCP training for investigators and CRCs
✔️ Strengthen CRO oversight through QA audits
✔️ Prepare inspection readiness plans at both sponsor and site levels
Proactive measures reduce inspection risks and build credibility with regulators.

Click to read the full article.

Clinical Trials in China, Country-Specific Clinical Trials

Post-COVID Clinical Research Resilience in China

Posted on digi By digi

Sponsors should:
✔️ Incorporate decentralized elements into trial protocols
✔️ Validate electronic systems for monitoring and eConsent
✔️ Diversify supply chains and invest in local manufacturing
✔️ Maintain flexible SOPs for protocol deviations
✔️ Strengthen CRO partnerships for crisis management
✔️ Engage regulators and ethics committees early in disruption scenarios
These practices create resilient clinical trial frameworks that can withstand future challenges.

Click to read the full article.

Clinical Trials in China, Country-Specific Clinical Trials

Oncology Biomarker-Driven Trials in China

Posted on digi By digi

Sponsors should:
✔️ Engage with NMPA and HGRAC early for biomarker and genomic testing approvals
✔️ Partner with Tier-1 hospitals and genomic laboratories for assay validation
✔️ Use standardized, globally recognized biomarker assays
✔️ Train site staff in biomarker testing and data management
✔️ Ensure data security and compliance with localization laws
✔️ Collaborate with CROs specializing in biomarker-driven trials
These practices reduce regulatory risks and improve trial efficiency.

Click to read the full article.

Clinical Trials in China, Country-Specific Clinical Trials